

2<sup>ND</sup>

# meeting of the European Research Consortium on ITP

NEW INSIGHTS INTO IMMUNE  
THROMBOCYTOPENIA



**Paris** Crowne Plaza Paris République

**April 23-24, 2026**

Sylvain **Audia** - Dijon, France  
 James B. **Bussel** - New York, USA  
 Nichola **Cooper** - London, UK  
 Etienne **Crickx** - Paris, France  
 Mario **Csenar** - Koeln, Germany  
 Waleed **Ghanima** - Oslo, Norway  
 Bertrand **Godeau** - Paris, France  
 Tomás José **González-López** - Burgos, Spain  
 Alice **Hart** - London, UK  
 Thomas **Kühne** - Basel, Switzerland  
 Maria Luisa **Lozano** - Murcia, Spain  
 Elisa **Lucchini** - Trieste, Italy  
 Matthieu **Mahévas** - Paris, France  
 Marc **Michel** - Paris, France  
 Guillaume **Moulis** - Toulouse, France  
 Andrew B. **Provan** - London, UK  
 Francesco **Rodeghiero** - Vicenza, Italy  
 Alexandra **Schifferli** - Basel, Switzerland  
 John W. **Semple** - Lund, Sweden  
 Karolin **Trautmann-Grill** - Dresden, Germany  
 Francesco **Zaja** - Trieste, Italy

## Thursday • April 23, 2026

01.30 pm REGISTRATION

01.45–02.00 pm WELCOME AND ERCI INTRODUCTION  
 M.L. Lozano, M. Michel

02.00-03.30 pm **SESSION 1 NEW INSIGHTS IN THE BIOLOGY AND DIAGNOSIS OF ITP**  
 Chairs: M. Michel, F. Zaja

- The role of platelets in innate and adaptive immunity – *J.W. Semple*
- Genetic predisposition for autoimmune cytopenias: lessons from Evans' syndrome – *E. Crickx*
- Predictive markers of treatment response: where do we stand? – *E. Lucchini*

03.30-04.00 pm Coffee break

04.00-05.30 pm **SESSION 2 GUIDELINES, DEFINITIONS AND REGISTRIES**  
 Chairs: M.L. Lozano, G. Moulis

- Updating definitions and outcome criteria in ITP: an ERCI IWG initiative – *F. Rodeghiero*
- The new EHA guidelines: current status – *M. Csenar, W. Ghanima*
- Why registries are useful: advances and gaps – *G. Moulis*

08.30–10.00 am **SESSION 3 ITP TREATMENT – ADDRESSING UNMET CLINICAL NEEDS AND FUTURE THERAPIES (PART 1)**

Chairs: T.J. González-López, T. Kühne

- Expanding the evidence on TPO-RAs in ITP through ERCI collaboration – *M.L. Lozano*
- Inhibiting Syk in ITP – *T.J. González-López*
- How BTK inhibitors may change the therapeutic approach in ITP – *N. Cooper*

10.00–10.30 am *Coffee break*

10.30 am–12.00 pm **SESSION 3 ITP TREATMENT – ADDRESSING UNMET CLINICAL NEEDS AND FUTURE THERAPIES (PART 2)**

Chairs: M. Michel, F. Rodeghiero

- Anti-CD38 monoclonal antibodies in ITP: current status – *W. Ghanima*
- Targeting BAFF/BAFF-R in ITP – *F. Zaja*
- Bispecific antibodies and CAR-T cells: do they have a place in ITP? – *K. Trautmann-Grill*
- Other novel therapeutic approaches (C1 inhibition, FcRn inhibition) – *S. Audia*

12.00–01.00 pm **SESSION 4 ITP IN SPECIFIC SITUATIONS**

Chairs: B. Godeau, F. Rodeghiero

- What's new in childhood/AYA ITP? – *T. Kühne, A. Schifferli*
- ITP during pregnancy: lessons from the last 5 years – *J.B. Bussel*
- Pharmacoeconomics of ITP: does cost matter? – *B. Godeau*

01.00–02.00 pm *Lunch*

02.00–03.30 pm **SESSION 5 QUALITY OF LIFE, ARTIFICIAL INTELLIGENCE, SECONDARY ITP**

Chairs: W. Ghanima, M.L. Lozano

- Quality of life in ITP – *A. Hart*
- What AI can bring to ITP – *A.B. Provan*
- Management of secondary ITP: what differs from primary ITP? – *M. Mahévas*

03.30–04.30 pm

**SESSION 6 ABSTRACT PRESENTATIONS**

Chairs: N. Cooper, A.B. Provan

- OC1.** EARLY T-CELL RECEPTOR REPERTOIRE FEATURES PREDICT LONG-TERM OUTCOME IN PAEDIATRIC IMMUNE THROMBOCYTOPAENIA – *A. Malik*
- OC2.** CIRCULATING CD8 T CELLS AS A POTENTIAL BIOMARKER OF NON-RESPONSE TO RITUXIMAB IN ITP – *R. Praliaux*
- OC3.** DARATUMUMAB CAN LEAD TO LONG-LASTING REMISSIONS IN PATIENTS WITH REFRACTORY IMMUNE THROMBOCYTOPENIA BUT WITH A HIGH INCIDENCE OF SEVERE INFECTIONS – *E. Han*
- OC4.** GENERATION OF SYNTHETIC PATIENTS IN IMMUNE THROMBOCYTOPENIA: EXPERIENCE FROM THE ITALIAN GIMEMA ITP0918 REGISTRY – *G. Marsili*
- OC5.** THE PROLONG TRIAL: A TWO PHASE RANDOMIZED PLACEBO-CONTROLLED TRIAL TO OPTIMIZE RITUXIMAB RESPONSE WITH DEXAMETHASONE AND MAINTENANCE THERAPY WITH LOW DOSE RITUXIMAB IN IMMUNE THROMBOCYTOPENIA – *W. Ghanima*
- OC6.** BCMA-TARGETING T-CELL-ENGAGER THERAPY INDUCES SUSTAINED REMISSION IN IMMUNE THROMBOCYTOPENIA – *M.L. Hütter-Krönke*

04.30-04.45 pm

CONCLUSIONS AND ANNOUNCEMENT OF NEXT ERCI MEETING  
*M.L. Lozano, M. Michel*

**CONGRESS VENUE**

**Crowne Plaza Paris République**

10 Pl. de la République - 75011 Paris (France)

**REGISTRATION FEES**

Registration Categories	Fee
Standard	€ 100,00
Exhibitor**	€ 60,00

**The standard registration fee includes:**

- Participation in the scientific sessions
- Conference kit
- Attendance certificate
- Lunches and coffee breaks

*\*\* Exhibitor fee DOES NOT include conference kit and participation in the scientific sessions*

**ABSTRACTS & POSTERS**

Abstract e-book will be available on the meeting website. Selected abstracts as poster will be displayed on site in the poster area.

**EBAH CME CREDITS**

The program of the 2<sup>nd</sup> European Research Consortium on ITP Meeting has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 9 CME credits for Physicians, Biologists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is mandatory to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

**OFFICIAL WEBSITE**

[www.erci2026.com](http://www.erci2026.com)

With the unrestricted educational grant of

PLATINUM



GOLD



SILVER



## ORGANIZING SECRETARIAT

### Studio E.R. Congressi

Via De' Poeti 1/7 - 40124 Bologna

Phone +39 051 4210559

[ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)

[www.ercongressi.it](http://www.ercongressi.it)

ER Congressi



## SCIENTIFIC COMMITTEE

**Meeting Chair:** M. Michel

**ERCI Co-Chairs:** T. Kühne, M.L. Lozano

**ERCI Board:** N. Cooper, W. Ghanima, T.J. González-López, T. Kühne, M.L. Lozano, G. Moulis, A.B. Provan, F. Rodeghiero, F. Zaja

## SCIENTIFIC SECRETARIAT ERCI

[erci@ercigroup.org](mailto:erci@ercigroup.org)

[www.ercigroup.org](http://www.ercigroup.org)